Journal Article Epublish
PubMed: 40161930 DOI: 10.34172/bi.29952
Effectiveness of dolutegravir in moderate severity COVID-19 patients: A single-center, randomized, double-blind, placebo-controlled trial.
Bioimpacts 15:29952
Authors: Hamideh Abbaspour Kasgari, Siavash Moradi, Ahmad Alikhani, Nasim Ahmadian
Affiliations
- Department of Clinical Pharmacy, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
- Education Development Center, Mazandaran University of Medical Sciences, Sari, Iran.
- Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
- Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran. Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
MeSH
Covid-19, Dolutegravir